创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

阿帕替尼致结直肠癌患者手足综合征发生风险及预测因素探讨

Analysis of the Risk and Predictive Factors of Apatinib-Induced Hand-Foot Syndrome in Patients with Colorectal Cancer

  • 摘要: 目的 探讨阿帕替尼致结直肠癌患者手足综合征(hand-foot syndrome,HFS)的发生风险及预测因素。方法 回顾性选取2019年1月至2023年6月于浙江大学医学院附属第一医院三门湾分院接受阿帕替尼治疗的219例结直肠癌患者,根据是否发生HFS分为发生组和未发生组。分析2组患者的一般资料和实验室检查结果,采用Logistic回归分析影响HFS发生的相关因素。结果 经治疗后因死亡等因素失访12例,共计纳入207例患者,其中发生组45例(21.74%),未发生组162例(78.26%)。发生组阿帕替尼剂量为500 mg的占比高于未发生组(P < 0.05)。发生组的谷丙转氨酶(alanine transaminase,ALT)、谷草转氨酶(aspartatetransferase,AST)、总胆红素(total bilirubin,TBil)、白细胞(white blood cell,WBC)水平高于未发生组(P < 0.05)。将上述差异有统计学意义的变量纳入多因素Logistic回归分析,结果显示,阿帕替尼剂量为500 mg(OR=2.568,95% CI: 1.159~5.689),WBC(OR=1.052,95% CI: 1.007~1.098),ALT(OR=1.141,95% CI: 1.067~1.220 ),AST(OR=1.181,95% CI: 1.064~1.310)以及TBil(OR=1.228,95% CI: 1.139~1.325)水平为阿帕替尼致HFS发生的危险因素(P < 0.05)。结论 阿帕替尼剂量为500 mg,以及WBC,ALT,AST,TBil水平高的患者经阿帕替尼治疗后更易发生HFS,故针对此类患者应综合评估HFS的发生风险,及时调整治疗方案,以预防HFS的发生。

     

    Abstract: Objective To investigate the risk and predictive factors of apatinib-induced hand-foot syndrome (HFS) in patients with colorectal cancer. Methods A retrospective analysis was conducted on 219 colorectal cancer patients treated with apatinib at the Sanmen Bay Branch of the First Affiliated Hospital of Zhejiang University School of Medicine from January 2019 to June 2023. Based on the occurrence of HFS, patients were divided into an occurrence group and a non-occurrence group. Baseline characteristics and laboratory test results of patients were compared between the two groups, and logistic regression analysis was performed to identify factors associated with HFS. Results After excluding 12 patients lost to follow-up due to death or other reasons, a total of 207 patients were included in the final analysis. Among them, 45 patients (21.74%) were in the occurrence group, and 162 patients (78.26%) were in the non-occurrence group. The proportion of patients receiving an apatinib dose of 500 mg was higher in the occurrence group compared with the non-occurrence group (P < 0.05). Additionally, the occurrence group showed significantly higher levels of alanine transaminase (ALT), aspartate transferase (AST), total bilirubin (TBil), and white blood cell (WBC) count (P < 0.05). Incorporating the variables with statistically significant differences from above into multivariate logistic regression analysis, the results show that an apatinib dose of 500 mg (OR=2.568, 95% CI: 1.159~5.689), WBC level (OR=1.052, 95% CI: 1.007~1.098), ALT level (OR=1.141, 95% CI: 1.067~1.220), AST level (OR=1.181, 95% CI: 1.064~1.310), and TBil level (OR = 1.228, 95% CI: 1.139 ~ 1.325) were identified as risk factors for apatinib-induced HFS (P < 0.05). Conclusion Patients receiving an apatinib dose of 500 mg or those with higher WBC, ALT, AST, and TBil levels are more susceptible to developing HFS following apatinib treatment. Therefore, for such patients, a comprehensive assessment of HFS risk should be conducted, and treatment plans should be adjusted promptly to prevent HFS occurrence.

     

/

返回文章
返回